This site is intended for health professionals only

EU approves breast cancer injection based on sea sponge


Europe has approved a new type of drug for breast cancer based on a product in the sea sponge.

Halaven (eribulin mesylate) has been licensed as third-line breast cancer therapy in patients with locally advanced or metastatic breast cancer who have failed on two previous courses of chemotherapy.

Prior regimens must have included an anthracycline and a taxane if the patient was eligible to receive these.
The decision follows the same approval by the FDA in November last year.

It is supported by the EMBRACE trial, a Phase III study that suggest eribulin mesylate boosted overall survival by a median of 2.5 months.

Eisai plans to launch eribulin mesylate across Northern Europe, beginning with the UK.

Eisai 2011

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine